ECCMID 2019 in Amsterdam

We will be at ECCMID 2019 with a poster contribution and as an exhibitor. The poster is on a novel cUTI mouse model and the application of PK/PD modelling to derive the required effect in the mouse model that translates to clinical response. We used historical Levofloxacin data to establish this animal-human translation. Visit us at our booth to learn more how we can support your preclinical, translational and clinical program with PK/PD modelling. … Read the rest


The Exposure Response Relationship of Enmetazobactam, Combined with Cefepime, is Best Described by f T > C T in a Murine Thigh Infection Model

F. Berhard 1, M. Machacek 1, P. Warn 2, R. Odedra 2, S. Sordello 2, A. Belley 3, P. Knechtle 3

1 LYO-X Allschwil CH; 2 Evotec Cheshire UK; 3 Allecra Therapeutics Saint-Louis FR

ASM-ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance • September 3-6, 2019 • Boston, MA.… Read the rest


Pharmacodynamic Targets of Enmetazobactam, Combined with Cefepime, against ESBL Producing Isolates of K. pneumoniae in a Murine Thigh Infection Model

P. Warn 1 , R. Odedra 1 , S. Sordello 1 , F. Berhard 2 , M. Machacek 2 , A. Belley 3 , P. Knechtle 3

1 Evotec Cheshire UK; 2 LYO-X Allschwil CH; 3 Allecra Therapeutics Saint Louis FR.  

ASM-ESCMID Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance • September 3-6, 2019 • Boston, MA.… Read the rest


Half-life extension and non-human primate pharmacokinetic safety studies of i-body AD-114 targeting human CXCR4

Katherine Griffiths, Uli Binder, William McDowell, Rita Tommasi, Mark Frigerio, William G. Darby, Chris G. Hosking, Lionel Renaud, Matthias Machacek, Peter Lloyd, Arne Skerra & Michael Foley. mAbs, 2019

Single domain antibodies that combine antigen specificity with high tissue penetration are an attractive alternative to conventional antibodies. However, rapid clearance from the bloodstream owing to their small size can be a limitation of therapeutic single domain antibodies. Here, we describe and evaluate the conjugation of a single domain i-body, AD-114, which targets CXCR4, to a panel of half-life extension technologies including a human serum albumin-binding peptide, linear and branched PEG, and PASylation (PA600).… Read the rest


LYO-X joint BEAM to Fight Antimicrobial Resistance

LYO-X joint the BEAM (Biotech companies in Europe combating AntiMicrobial Resistance) alliance, a strong Network of ~ 50 European biopharmaceutical companies committed to developing innovative products to fend-off antibiotic-resistant pathogens.

We have continuously expanded our support of biotech companies with PK/PD modelling and SystemsPharmacology to translate their antibiotics more effectively to patients. Helping biotechnology companies to succeed and bringing new antibiotics to patients is something we feel really committed to.

By joining BEAM we hope to help even more biotechs to bring their drugs to patients and to increase the awareness of PK/PD modelling as a tool for efficient antibiotics drug development.… Read the rest


‘In-silico Drug Development, Modelling & Simulation’ at the University of Freiburg

LYO-X will give a lecture + hands on seminar on ‘In-silico Drug Development, Modelling & Simulation’ at the University of Freiburg for Pharmacy Master Students. This is together with Dr. Regenold GmbH who will be covering complementary topics on preclinical and clinical drug development . We are looking forward to engage the students and to give them a real world perspective on how in silicon methods are used today to develop novel drugs.… Read the rest


Postdoctoral position

Automated skin lesion detection and severity classification using image analysis and machine learning. Unique opportunity to boost your career in Switzerland as an outstanding researcher. Application deadline: July 15. 2018. See our career website for more details.… Read the rest


Poster presentation at PAGE 2018

Systems Pharmacology model of peripheral serotonin production proposing two different synthesis compartments with markedly different release rates into blood. Link to abstract

M. Machacek (1), L. Renaud (1), C. Kohl (2), M. Vercauteren (2), L. Remen (2), R. Welford (2). (1) LYO-X GmbH, Ringstrasse 9, 4123 Allschwil, Switzerland. (2) Idorsia Pharmaceuticals Limited, Hegenheimermattweg 91, 4123 Allschwil, Switzerland… Read the rest